PURPOSE: Secernin 1 (SCRN1) is a member of the secernin family and is reported to be a tumor-associated antigen. Previous reports show that SCRN1 is upregulated in gastric cancer cell lines and may be a novel immunotherapy target, whereas its significance in colorectal cancer (CRC) is not fully understood. MATERIALS AND METHODS: The present study comprised 54 patients who underwent surgery for CRC, as well as two cell lines derived from human CRC. We assessed the correlation of gene expression with clinical parameters in the CRC patients, and knockdown was evaluated in the cell lines. RESULTS: Thirty of the 54 (55.5%) cases exhibited a higher expression of the SCRN1 gene in cancerous regions than marginal non-cancerous regions. Patients with high SCRN1 expression were statistically susceptible to a poor prognosis and showed poorer disease-free survival than those with low expression. SCRN1 knockdown in the two cell lines demonstrated that the siRNA inhibition resulted in a statistically significant reduction in cell growth. CONCLUSION: The present data strongly suggest that SCRN1 expression is a prognostic factor in CRC patients.
PURPOSE:Secernin 1 (SCRN1) is a member of the secernin family and is reported to be a tumor-associated antigen. Previous reports show that SCRN1 is upregulated in gastric cancer cell lines and may be a novel immunotherapy target, whereas its significance in colorectal cancer (CRC) is not fully understood. MATERIALS AND METHODS: The present study comprised 54 patients who underwent surgery for CRC, as well as two cell lines derived from human CRC. We assessed the correlation of gene expression with clinical parameters in the CRC patients, and knockdown was evaluated in the cell lines. RESULTS: Thirty of the 54 (55.5%) cases exhibited a higher expression of the SCRN1 gene in cancerous regions than marginal non-cancerous regions. Patients with high SCRN1 expression were statistically susceptible to a poor prognosis and showed poorer disease-free survival than those with low expression. SCRN1 knockdown in the two cell lines demonstrated that the siRNA inhibition resulted in a statistically significant reduction in cell growth. CONCLUSION: The present data strongly suggest that SCRN1 expression is a prognostic factor in CRC patients.
Authors: Guido Marcucci; Pearlly Yan; Kati Maharry; David Frankhouser; Deedra Nicolet; Klaus H Metzeler; Jessica Kohlschmidt; Krzysztof Mrózek; Yue-Zhong Wu; Donna Bucci; John P Curfman; Susan P Whitman; Ann-Kathrin Eisfeld; Jason H Mendler; Sebastian Schwind; Heiko Becker; Constance Bär; Andrew J Carroll; Maria R Baer; Meir Wetzler; Thomas H Carter; Bayard L Powell; Jonathan E Kolitz; John C Byrd; Christoph Plass; Ramiro Garzon; Michael A Caligiuri; Richard M Stone; Stefano Volinia; Ralf Bundschuh; Clara D Bloomfield Journal: J Clin Oncol Date: 2013-12-30 Impact factor: 44.544
Authors: Brendan J Houston; Liina Nagirnaja; D Jo Merriner; Anne E O'Connor; Hidenobu Okuda; Kenan Omurtag; Craig Smith; Kenneth I Aston; Donald F Conrad; Moira K O'Bryan Journal: Dev Dyn Date: 2021-01-25 Impact factor: 3.780
Authors: Thomas Sanford; Paul H Chung; Ariel Reinish; Vladimir Valera; Ramaprasad Srinivasan; W Marston Linehan; Gennady Bratslavsky Journal: PLoS One Date: 2011-07-27 Impact factor: 3.240
Authors: Cordelia Geisler; Nadine T Gaisa; David Pfister; Susanne Fuessel; Glen Kristiansen; Till Braunschweig; Sonja Gostek; Birte Beine; Hanna C Diehl; Angela M Jackson; Christoph H Borchers; Axel Heidenreich; Helmut E Meyer; Ruth Knüchel; Corinna Henkel Journal: Biomed Res Int Date: 2015-01-15 Impact factor: 3.246